TEV 45478

Drug Profile

TEV 45478

Alternative Names: TEV-45478

Latest Information Update: 26 Nov 2016

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 16 Nov 2016 Teva suspends enrolment in a phase II trial for Non-alcoholic steatohepatitis in Israel, due to business decisions (NCT02769091)
  • 01 Sep 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in Israel (PO) (NCT02769091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top